Growth factor withdrawal from proliferating myoblasts induces the expression of muscle-specific genes essential for myogenesis. By suppression subtractive hybridization (SSH), we have cloned a novel human cDNA that encodes a Cys3His zinc finger protein named CHCR (Cys3His CCG1-Required). CHCR is related to Muscleblind (Mbl), a Drosophila melanogaster protein required for terminal muscle differentiation. It also displays sequence similarity to EXP/MBNL, a human Mbl protein that interacts with CUG expansions associated with the degenerative muscular disease, myotonic dystrophy (DM1). This relationship with EXP/MBNL and Mbl suggests that CHCR also functions during muscle differentiation. We have found that CHCR mRNA and protein levels decrease upon differentiation of mouse myoblast cells. 
INTRODUCTION
Myogenesis is a highly ordered and regulated process that can be temporally separated into four distinct events (Andres and Walsh, 1990) . First, upon mitogen withdrawal, the muscle specific, basic helix-loop-helix transcription factor MyoD is activated, leading to the induction of myogenin and other myogenic factors. Myogenin expression marks the commitment of myoblasts to the differentiation pathway (Sabourin and Rudnicki, 2000) . Second, irreversible cell cycle arrest is triggered by an increase in the cyclindependent kinase inhibitor, p21 (Lassar et al., 1994; Walsh and Perlman, 1997) . Third, expression of terminal differentiation markers, including sarcomeric MyHC and muscle creatine kinase occurs in the differentiating cells (Clegg et al., 1987) . Finally, fusion of the differentiated myocytes leads to the formation of multinucleated myotubes and functional muscle. Perturbing any stage of this myogenic program will result in compromised muscle development.
One protein that is required for the terminal stages of muscle differentiation in Drosophila melanogaster is Muscleblind (Mbl). Mbl was cloned in a genetic screen designed to isolate genes that suppress the excessive photoreceptor phenotype of sev-svp2 mutant flies (Begemann et al., 1997) . In addition to its role in photoreceptor formation, Mbl is expressed late in larval development in the larynx, pharyngeal, and visceral and somatic musculature, and is required for terminal differentiation of these tissues (Artero et al., 1998) . Mbl mutant-flies are unable to properly organize the Z-bands in the sarcomeric apparatus resulting in paralysis and embryonic lethality. A mammalian homologue of Drosophila Mbl, EXP/MBNL, has been cloned as a polypeptide that binds to CUG repeat expansions responsible for the degenerative muscular disorder, myotonic dystrophy (DM1) (Brook et al., 1992; Fu et al., 1992; Mahedevan et al., 1992; Miller et al., 2000) . The expression of EXP/MBNL is induced as cells undergo muscle differentiation. These findings, taken together, suggest that Mbl and its mammalian homologue, EXP/MBNL, are required to promote the muscle differentiation pathway.
Our studies of cell cycle-related genes intersected with the EXP/MBNL muscle differentiation pathway described above when we attempted to identify proliferation genes in ts13 cells. ts13 cells are temperature-sensitive BHK-21 (baby hamster kidney) mutants that exhibit a proliferative defect when grown at the nonpermissive temperature of 39.5°C (Talavera and Basilico, 1977) . The mutant cells arrest in late G 1 due to a mutation in the CCG1/TAF II 250 gene (Hayashida et al., 1994) . While BHK-21 cells were derived from the kidney, it has been demonstrated that they are myofibroblasts that express a wide variety of musclespecific markers, such as troponin, MyHC, and MyoD (Mayer and Leinwand, 1997; Van der Ven and Furst, 1998) . In addition, the muscle creatine kinase enhancer is equally active in BHK-21 and C2C12 myoblast cells upon serum deprivation. Myofibroblasts have been referred to as "crossdressers" in that they express a large number of musclespecific proteins but do not fuse into myotubes under differentiation conditions (Walker et al., 2001) . Therefore, ts13 myofibroblast cells exhibit the unique trait of expressing both muscle-specific and nonmuscle proteins. By suppression subtractive hybridization (SSH), we have cloned a novel human cDNA encoding a Cys3His zinc finger protein that we named CHCR (Cys3His CCG1-Required). The coding region for CHCR was very recently identified by another group in a database search for proteins similar to MBNL (Fardaei et al., 2002 ). CHCR's high degree of sequence homology to Mbl led us to hypothesize that CHCR plays a role in myogenesis. While Mbl is involved in promoting muscle differentiation, CHCR appears to function in an opposing manner. We have found that constitutive expression of CHCR in C2C12 mouse myoblasts strongly inhibits the induction of MyHC, and to a lesser extent, the earlier differentiation marker, myogenin. CHCR does not, however, affect the induction of the cell cycle inhibitor p21. Treatment of C2C12 cells with morpholino antisense oligonucleotides, which reduced CHCR protein levels, results in the acceleration of MyHC expression in the presence of low serum. These data suggest that CHCR differs from other members of the muscleblind family of proteins by functioning as an inhibitor of terminal muscle differentiation. Therefore, a delicate balance between positive and negative regulators is critical for the proper execution of the myogenic program.
MATERIALS AND METHODS

Tissue Cell Culture
Hamster ts13 cells were grown at 33.5°C, and the rescued ts13 cell line (ts13R3) was passaged at 39.5°C. The hamster cell lines, HEK293 cells, and C2C12 mouse myoblast cell line were maintained in growth media (GM) consisting of DME and 10% FBS. For differentiation assays, C2C12 cells were plated into collagencoated tissue culture plates in GM for 24 h. Growth medium was then replaced with DME supplemented with 0 or 2% horse serum, and 10 ng/ml insulin, 5.5 g/ml transferrin, and 10 ng/ml selenium (DM). MM14 mouse myoblasts were grown exponentially in Ham's F10C nutrient medium supplemented with 15% horse serum and 3 ng/ml basic FGF as described by Neville et al. (1997) . To initiate differentiation, the growth medium was aspirated and cultures were washed twice with saline G solution. Medium was then replaced with F10C supplemented with 1.5% horse serum and 1 M insulin. The cells were allowed to differentiate for 2-4 days, replacing media every 2 days as necessary. Collagen (C-7661) and the insulin, transferrin, selenium supplement (I-3146) were purchased from Sigma.
Suppression Subtractive Hybridization
ts13 cells were synchronized in G0 by serum starvation at 33.5°C. After the addition of media containing 10% FBS, cells were maintained at 33.5°C (tracer) or shifted to 39.5°C (driver). Approximately 16 -18 h post-serum addition, mRNA was harvested by using the Fasttrack 2.0 Kit from Invitrogen. The driver pool was subtracted from the tracer pool by using the technique of SSH as described (Diatchenko et al., 1996) . To control for heat shock effects, ts13 and ts13R3 cells were serum starved at 33.5°C. Both cell lines were then shifted to 39.5°C after serum addition, and mRNA was harvested after 16 -18 h. The driver pool (ts13) was subtracted from the tracer (ts13R3).
Cloning of Human CHCR and Plasmid Constructs
Human HeLa gt11 cDNA library was purchased from Clontech. The 5Ј end of the human CHCR cDNA was cloned from the human gt11 cDNA library by using the gt11 reverse primer and N-term 30 mer (5Ј-AAAGAACCAAGTGATGACATTTGATCGTT-3Ј) in a modified 5Ј RACE protocol in which the initial denaturing step was carried out at 98°C for 10 min. The sequence of the 3Ј portion of human CHCR was obtained from an EST (Accession No. AA460149). Additional overlapping CHCR EST's include Accession Nos. AA912517, AU157931, and AI970137. Primers 5Ј-GAA-TTCAATATGACGGCTGTCAATGTTGCC (CHCR ATG primer) and 5Ј-GGAATTCGTTACATCCTGAATCAACCCAAT-3Ј (CHCR 3Ј cloning primer) were used to PCR amplify a contiguous human CHCR ORF from HEK293 cDNA synthesized by using oligo(dT) n and random primers at a 1:1 ratio. Human CHCR cDNA, as an EcoRI fragment, was subcloned into the EcoRI site of pBlueScript to generate pBS-hCHCR. The eukaryotic expression vector CS2ϩmt-hCHCR was constructed by subcloning the EcoRV to XbaI fragment of human CHCR from pBS-hCHCR between the StuI and XbaI sites of CS2ϩmt.
(EMBL-EBI and Sanger Institute) identified a number of genomic sequences (trace file, G10P634271FF4.T0, mk2A-a4097b06.p1c, G10P6011522FF9.T0, G10P678399FH2T0) that encode for portions of mouse CHCR. These sequences were used to generate a mousespecific sense primer (5Ј-CGGATCCAAGAGGGTGCACTTGAT-TGCC-3Ј) located 35 bp upstream of the initiator methionine, and an antisense primer (5Ј-CGGAATTCACACGGAGTTTCTTGT-TGAGA-3Ј) positioned 49 bp downstream of the termination codon. These primers were used to amplify the entire coding region of mouse CHCR by RT-PCR from 1 g total RNA isolated from the mouse myoblast cell line, C2C12. RT-PCRs were incubated for 30 min at 50°C, followed by 35 cycle of: 15 s at 94°C, 20 s at 55°C, and 2 min at 72°C. The mouse CHCR sequence has been submitted to GenBank (Accession No. AF466292). The mouse CHCR cDNA was subcloned into the EcoRI site of the CS2ϩ expression vector (CS2ϩmCHCR) and confirmed by DNA sequencing.
Generation of Polyclonal Antiserum against Mouse CHCR
The carboxy-terminal 83 amino acids of the mouse CHCR protein (residues 259 to 342) were subcloned between the BamHI and EcoRI sites of the pGEX-KT expression vector and expressed as a GST fusion protein in bacteria. Bacteria transformed with the pGEX-KT C-term mCHCR expression plasmid were grown in LB ϩ 100 g/ml ampicillin at 25°C to OD 600 of 0.2. Expression was induced with the addition of 0.4 mM IPTG and proceeded for 24 h at 30°C. Cell lysates prepared in STE buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA) were incubated with 10 l of a 75% slurry of glutathione sepharose (Pharmacia) for 1 h at 4°C, and bound proteins eluted with 20 mM glutathione in STE. Eluted proteins were separated by SDS-PAGE and full-length GST-C-term mCHCR was excised from the gel and used to immunize a rabbit (Harlan BioProducts).
Retrovirus Infection of C2C12 Cells
Recombinant retrovirus, which produces a single message containing the entire coding region for mouse CHCR upstream of an internal ribosomal entry site followed by the coding region for GFP, was constructed by Jason Fontenot in the laboratory of Dr. Alexander Rudensky. C2C12 cells were plated into 24-well plates at a density of 2 ϫ 10 4 cells/well. The media was replaced with 1 ml of retrovirus expressing either GFP or GFP and mouse CHCR (untagged). C2C12 cells were infected by centrifugation of the plates at 2500g for 90 min at 37°C in the presence of 8 g/ml polybrene, followed by incubation overnight at 33°C. The retroviruscontaining medium was then replaced with growth media, and the infected population was expanded to approximately 5 ϫ 10 6 total cells. GFP-positive cells were isolated by sterile FACS sorting.
Preparation of Cell Extracts and Western Blotting
Whole cell extracts were prepared by using a lysis buffer containing 50 mM Tris-HCl (pH 7.5), 400 mM NaCl, 1% NP-40, 1 mM DTT, and protease inhibitors. For Western blotting, lysates were subjected to SDS-PAGE, and proteins were transferred onto nitrocellulose or PVDF membrane. Western blots were incubated with the appropriate antibodies overnight at 4°C followed by either alkaline phosphatase-or horseradish peroxidase-conjugated secondary antibody. Antibodies against sarcomeric MyHC (mAb MF20) and myogenin (mAb F5D) were obtained from the Developmental Studies Hybridoma Bank (DSHB) developed under the auspices of the NICHD and maintained by the University of Iowa, Department of Biological Sciences, Iowa City, IA 52242. The anti-p21 antibody (C-19) was purchased from Santa Cruz Biotechnology and the anti-␣-tubulin (mAb DM 1A) was purchased from Sigma. The cell line for the anti-myc mAb 9E10 was kindly provided by Dr. Randall Moon.
RT-PCR and Primers
Total RNA was isolated from MM14 and C2C12 mouse myoblast cell lines by using the Trizol Reagent from Gibco-BRL. RT-PCR was performed by using the Superscript One-Step RT-PCR with Platinum Taq kit (Gibco-BRL). The mouse CHCR primers used in the RT-PCRs are 5Ј-TCAGGGTCGGTGCACTC-3Ј and 5Ј-AGAAATCAGAACCGGACCAT-3Ј, and are located within two adjacent exons. The sequences of the G3PDH primers are 5Ј-ACCACAGTCCATGCCATCAC-3Ј and 5Ј-TCCACCACCCT-GTTGCTGTA-3Ј. RT-PCRs using total RNA from C2C12 myoblasts as template, were performed as follows: 1 cycle at 50°C for 30 min; 1 cycle at 94°C for 2 min; 27 cycles at 94°C for 15 s, 55°C for 30 s, and 72°C for 45 s. Reactions using total RNA from MM14 myoblasts were performed with a similar PCR protocol, except that the number of amplification cycles was increased from 27 to 35.
In Vitro Transcription/Translation Reactions
Complementary DNA for mouse MBNL was synthesized by RT-PCR using primers based on sequence information available in the GenBank database (Accession No. NM_020007) and subcloned into the EcoRI site of the CS2ϩ expression vector. In vitro protein synthesis of mouse CHCR and mouse MBNL proteins was performed by using the Promega TNT SP6 Coupled Reticulocyte Lysate Kit. One microgram of CS2ϩmCHCR or CS2ϩmMBNL plasmid DNA was used as template in transcription/translation assays. The reactions were carried out in a 15-l volume and scaled down proportionally to the manufacturer's protocol. The sequence of the mouse CHCR morpholino antisense oligonucleotide is 5Ј-GCCAATTTGCTCTCAGTATGACAC-3Ј. The standard control oligonucleotide was purchased from GeneTools.
In Vivo Treatment with Morpholino Antisense Oligonucleotides
C2C12 cells were seeded into six well plates in growth media at a density of 8 ϫ 10 5 cells/well. The following day, the media was replaced with DM (2% horse serum) containing 10 M mCHCR-AS or a standard control morpholino available from GeneTool. The cells were then immediately scraped off the plates in order to deliver the oligonucleotides into the cells. Finally, the morpholinoloaded cells were quickly transferred into collagen-coated six well plates, allowed to attach in DM, and differentiated at 37°C for 2 days. Scrape delivery of the morpholino oligonucleotides was carried out essentially as described by GeneTools (http://www. gene-tools.com/).
RESULTS
Cloning of Human CHCR
ts13 cells are temperature-sensitive mutant BHK-21 cells that arrest in the late G 1 phase of the cell cycle at the nonpermissive temperature (39.5°C) due to a mutation in the transcription factor CCG1/TAF II 250 (Hayashida et al., 1994) . To identify genes regulating passage through G 1 , we carried out a SSH screen with cDNA generated from ts13 cells grown at the permissive (33.5°C) and nonpermissive temperatures. Because the cells were maintained at two different temperatures, we wanted to eliminate changes in gene expression that could be attributed to heat shock effects. We therefore performed a second SSH screen using pools of cDNA generated from two different cell lines, which were both maintained at 39.5°C. The two cell lines used were the mutant ts13 cells and a "rescued" ts13 cell line (ts13R3), which constitutively expresses wild-type CCG1/TAF II 250 and no longer cell cycle arrests at 39.5°C.
We focused our efforts on a 340-bp, partial cDNA fragment that was isolated in both screens and confirmed by Northern blot analysis to be expressed only in permissively grown ts13 cells (data not shown). The encoded protein fragment was found to display significant homology to Mbl, a D. melanogaster protein required for proper muscle development (Artero et al., 1998) . The region of Mbl that aligns with this novel protein fragment contains an unusual Cys3His zinc finger motif. We therefore named this newly cloned protein CHCR for Cys3His CCG1-Required.
We then cloned the full-length human CHCR cDNA to use for future functional studies (Fig. 1A) . Using the hamster CHCR cDNA fragment as a probe, we isolated an 800-bp human cDNA (1A1) that encodes the central portion of human CHCR from a gt11 HeLa library. A modified RACE procedure was used to isolate the missing 5Ј end of the CHCR cDNA, including the initiator methionine and 79 bp of 5Ј untranslated region (UTR). A search of the GenBank human EST (expressed sequence tags) database identified several overlapping sequences exhibiting 100% identity with the 1A1 human CHCR clone. Based on the sequence of the ESTs and 5Ј RACE product, we designed a primer set to amplify a cDNA encoding the complete human CHCR open reading frame plus 491 bp of 3Ј UTR from human embryonic kidney (HEK) 293 cells. When a myc-epitope tagged version of the hCHCR cDNA was transiently expressed in ts13 cells, a single polypeptide was recognized by the anti-myc monoclonal antibody 9E10 only in extracts prepared from transfected cells (Fig. 1B) .
Human Muscleblind Protein Family
Human CHCR contains two pairs of Cys3His motifs, unusual zinc finger domains, flanking a central proline-rich region ( Figs. 2A and 2B ). The spacing between the cysteine and histidine residues present in motifs 1 and 3 are identical (CX7CX6CX3H and X ϭ any amino acid), whereas motifs 2 and 4 have the unique spacing pattern of CX7CX4CX3H that is not found in any other known Cys3His-containing protein. In addition to displaying significant amino acid identity (43%) with Drosophila Mbl (Fig. 3A) , CHCR also exhibits 45% similarity to the Caenorhabditis elegans protein K02H8, thought to be the worm homologue of Mbl.
In humans, the EXP/MBNL and MBLL proteins are highly related to CHCR (Figs. 3A and 3B ). EXP/MBNL has been implicated in muscle development, while the cellular function of MBLL is currently unknown. All three of the mammalian proteins (CHCR, EXP/MBNL, MBLL) possess significant amino acid identity with Mbl (ϳ45%), as well as ϳ70% overall identity among each other, suggesting that they represent a unique protein family. The Cys3His motifs are highly conserved and are Ͼ90% identical between the human Mbl family members. In fact, the spacing between the cysteines and histidine in motifs 2 and 4 in CHCR is unique to the vertebrate Mbl proteins further strengthening the hypothesis that CHCR, EXP/MBNL, and MBLL comprise a family of mammalian Mbl homologues. 
CHCR mRNA Levels Decrease in Differentiating MM14 and C2C12 Myoblasts
The expression of EXP/MBNL has been reported to increase as replicating myoblasts are induced to differentiate (Miller et al., 2000) . The striking sequence similarity between CHCR and EXP/MBNL led us to investigate the expression pattern of CHCR in proliferating and differentiated MM14 and C2C12 mouse myoblast cells. MM14 cells remain in the proliferative state when cultured in media containing high serum and the anti-differentiation growth factor, basic FGF, and can be induced to differentiate upon removal of basic FGF and addition of insulin (Clegg et al., 1987) . C2C12, a second well-characterized mouse myoblast cell line, will undergo differentiation when shifted from high serum to media containing 0 or 2% horse serum and insulin.
We observed by RT-PCR that CHCR mRNA is nearly undetectable in differentiated MM14 cells and dramatically reduced in differentiated C2C12 cells compared with their proliferating counterparts (Fig. 4) . Nearly 100% of the MM14 cells and approximately 50% of C2C12 cells have entered the late stage of muscle differentiation as determined by staining for sarcomeric MyHC, a biochemical marker for the terminal stage of muscle differentiation (data not shown). Expression of the housekeeping gene glyceraldehyde 3-phosphate dehydrogenase (G3PDH), used to control for mRNA input, was unchanged. These findings are in sharp contrast to what has been described for EXP/MBNL. The EXP/MBNL protein is undetectable in proliferating C2C12 cells (Miller et al., 2000) . During muscle differentiation EXP/MBNL is not detected until day 2 and increases to a maximal level by day 4. These data, taken together, suggest that CHCR is expressed in a manner consistent with a potential role in modulating the differentiation state of myogenic cells.
Constitutive CHCR Expression in C2C12 Myoblasts Inhibits Myosin Heavy Chain and Myogenin Induction, but Not p21, During Muscle Differentiation
The downregulation of endogenous CHCR mRNA levels during muscle differentiation led us to hypothesize that completion of the myogenic program requires a reduction in CHCR activity. According to this speculative hypothesis, we predict that constitutive expression of CHCR in myoblasts will inhibit muscle differentiation. To test this hypothesis, we generated G418-resistant C2C12 clonal cell lines that stably express myc-tagged human CHCR (mt-CHCR) along with a number of control G418-resistant clones not expressing mt-CHCR (Fig. 5A) . Control (C7) and mt-CHCR expressing C2C12 clones (E6) were plated on collagen-coated plates in growth medium (GM) containing 0.4 mg/ml G418. The cells were induced to differentiate by shifting to differentiation media (DM). As a measure of muscle differentiation, the protein levels of sarcomeric MyHC, a terminal differentiation marker, were monitored by Western blot analysis. As expected, induction of MyHC was detected in the control C2C12 clone as cells differentiated over a 5-day period in DM (Fig. 5B, lanes 1-6) . Consistent with our hypothesis, the extent of MyHC induction was compromised significantly in the mt-CHCR expressing clone (Fig. 5B, lanes 7-12) . The protein levels of ␣-tubulin, used to control for differences in protein loading, remained unaltered indicating that mt-CHCR does not have a global effect on gene expression (Fig. 5) .
We have examined a total of six independently isolated mt-CHCR expressing clones, all of which display compromised MyHC induction in low serum (data not shown). By contrast, no decrease in MyHC expression was observed with any of the G418-resistant control C2C12 clones (total of 5) analyzed in parallel. Therefore, we do not believe that selection for differentiation-deficient C2C12 myoblasts has occurred in our studies. Additional experiments designed to further address this concern are described later.
"Commitment" to muscle differentiation requires the expression of the bHLH protein, myogenin, and precedes the terminal stages of myogenesis (Andres and Walsh, 1990). Hindering the synthesis of cellular factors upstream of MyHC in the muscle differentiation pathway could also result in a dramatic decrease in MyHC protein levels. We therefore examined the expression levels of the early myogenic marker, myogenin, in control and mt-CHCR expressing C2C12 cells after placing them in DM. Under conditions that result in a sixfold reduction in MyHC protein levels in mt-CHCR expressing C2C12 cells, only a twofold decrease in myogenin was observed by western blot analysis (Fig. 5C ). These findings suggest that CHCR acts prior to the terminal stages of muscle differentiation at approximately the time of myogenin induction.
Once myoblasts commit to become muscle tissue, they must then withdraw from the proliferative cell cycle. This event is marked by the induction of the cell cycle inhibitor, p21, which is paramount for the differentiation pathway to proceed to the terminal stages (Andres and Walsh, 1990) . We therefore performed Western blot analysis on mt-CHCR-expressing and control C2C12 cells during the course of differentiation to investigate whether CHCR blocks p21 induction. Interestingly, the protein levels of the cell cycle inhibitor p21 were unaffected by CHCR expression (Fig. 5D ). These data indicate that CHCR function precedes the terminal stage of muscle differentiation, but is not required for cell cycle arrest.
Overexpression of Mouse CHCR in a Population of C2C12 Cells Inhibits Myosin Heavy Chain Induction
To eliminate the possibility of isolating differentiationdefective cells through clonal selection techniques, we introduced mouse CHCR into a population of C2C12 myoblasts by retroviral infection. The ability to examine a population of CHCR overexpressing cells, which maintain a diverse genetic background, will avoid any experimental pitfalls associated with traditional clonal selection. We also decided to express the endogenous mouse protein in these experiments to eliminate potential artifacts due to the introduction of an epitope-tagged human protein into mouse cells.
The first step was to clone and express the cDNA for mouse CHCR (mCHCR). To this end, the human CHCR sequence was used to perform a homology search of both the GenBank EST database and the mouse Ensembl Trace genomic shotgun database. While there was no EST sequence which included the initiator methionine of mouse CHCR, a number of genomic sequences encoding several portions of mouse CHCR fortuitously included the start and stop codons. This sequence information allowed us to generate a sense primer 35 bp upstream of the ATG and an antisense primer 49 bp downstream of the translational termination codon. By RT-PCR, a mouse CHCR cDNA (1113 bp) encompassing the entire ORF (1029 bp) was amplified from total RNA isolated from proliferating C2C12 mouse myoblasts. Nucleotide sequencing and the deduced amino acid sequence revealed that the mouse protein is 342 amino acids and has a pI of 9. Like the human CHCR protein, mouse CHCR possesses four characteristic Cys3His, zinc finger motifs flanking a central proline-rich region. The two CHCR proteins are 81% identical at the amino acid level, varying only at the carboxyl terminus (Fig.  6) . Having cloned mouse CHCR, the cDNA was used to generate a recombinant retrovirus that produces a single message including the coding region for mCHCR followed by an internal ribosomal entry site upstream of the coding   FIG. 4 . CHCR mRNA levels decrease in differentiated mouse myoblasts. RT-PCR analysis was performed by using primers designed against a 280-bp trans-exon region of the mouse CHCR gene. Intron/exon boundaries for the mouse gene were identified by aligning the mouse CHCR cDNA (Accession No. AF466292) with shotgun genomic sequences deposited in the Ensembl Trace database. Total RNA was harvested from proliferating MM14 and C2C12 myoblast cells grown in GM, and differentiated MM14 and C2C12 cells grown in DM for 4 (C2C12) or 5 (MM14) days. A total of 0, 50, or 500 ng total RNA was used for RT-PCRs. RT-PCR of the housekeeping gene, G3PDH, was performed with 0, 1, or 10 ng total RNA to control for reverse transcriptase efficiency and RNA input. PCR products were separated on 1.2% agarose gel and visualized by ethidium bromide staining.
region for the green fluorescence protein (GFP). The presence of GFP and mCHCR on the same mRNA molecule allowed for the selection of a population of mouse CHCR overexpressing cells by sterile FACS sorting for GFPpositive cells. As a control, cells infected with a recombinant retrovirus that only contains the GFP coding region 1 and 2) , and mt-CHCR-expressing (lanes 3 and 4) C2C12 clones were separated on 12% SDS-polyacrylamide gel and subjected to Western blot analysis by using the anti-myc mAb 9E10. (B) Control (C7) and mt-CHCR-expressing (E6) C2C12 clones maintained in growth media for 24 h were induced to differentiate by shifting the cells to differentiation media (DM). The expression of MyHC was determined by immunoblotting whole cell lysates after 0 (lanes 1, 7), 1 (lanes 2, 8), 2 (lanes 3, 9), 3 (lanes 4, 10), 4 (lanes 5, 11), and 5 (lanes 6, 12) days in DM using the anti-MyHC mAb MF20. The ␣-tubulin levels also were monitored by Western blot analysis. The relative amount of MyHC normalized for ␣-tubulin was determined. (C) Same as (B), except lysates were immunoblotted with anti-myogenin monoclonal antibody (mAb F5D) and quantified. (D) Control (C7) and mt-CHCR (E6)-expressing C2C12 clones were grown in DME containing 10% FBS. After 24 h, cells were switched to DM and harvested after 0 (lanes 1, 4), 1 (lanes 2, 5), and 2 (lanes 3, 6) days. Whole-cell extracts were immunoblotted with antibodies against p21 (C-19) and ␣-tubulin (mAb DM 1A). The fold induction of p21 protein levels, after normalization for ␣-tubulin levels, are shown in graphic form. The data presented in (B-D) are from one representative experiment and have been repeatedly observed and with several independently isolated clones.
were sorted in parallel. To confirm expression of the untagged mouse CHCR protein in the GFP/mCHCR cell population, we generated a polyclonal antiserum against the carboxy terminus of mouse CHCR. Western blot analysis using the anti-mCHCR antiserum revealed a single, predominant 45-kDa band in GFP infected cells that is presumed to represent the endogenous mCHCR (Fig. 7A) . The intensity of this band in the GFP/mCHCR cell population was significantly increased, providing further evidence that the 45-kDa polypeptide was indeed mCHCR, and that mCHCR had been successfully overexpressed in these cells (Fig. 7A) .
Having established the overexpression of mCHCR in C2C12 cells, we then tested the ability of the two populations of GFPϩ cells to undergo differentiation by monitoring MyHC levels (Fig. 7B) . We observed that a significant increase in MyHC levels was detected in the control infected cells after 2 days in DM. No detectable induction was observed with the pool of C2C12 cells that overexpress mCHCR. It should be noted that the endogenous levels of mCHCR were found to decrease in C2C12 cells after 2 days in differentiation conditions, which parallels the reduction in mRNA levels initially observed by RT-PCR. Therefore, the results of a second independent method for overexpressing mCHCR in C2C12 cells support our initial conclusion that CHCR hinders the induction of MyHC and suggests that, in contrast to Mbl, CHCR is an inhibitor of muscle differentiation.
Morpholino Antisense Oligonucleotides Targeting Mouse CHCR Accelerates MyHC Induction in Differentiating C2C12 Mouse Myoblasts
To complement the gain-of-function studies described above, we adopted a morpholino antisense oligonucleotide strategy to reduce CHCR protein levels in C2C12 cells. To carry out the loss-of-function studies, a morpholino antisense oligonucleotide was designed that specifically targets the 5Ј UTR and translational start codon of mouse CHCR (mCHCR-AS), but not the highly related mouse MBNL protein. The specificity and effectiveness of the morpholino oligonucleotide was tested by adding increasing concentrations of mCHCR-AS to an in vitro transcription/translation system containing a mCHCR cDNA expression plasmid. In the absence of any oligonucleotide, a single polypeptide similar in size to the endogenous protein detected by the anti-mCHCR antiserum was translated in the cell-free system (Fig. 8A, lane 1) . Addition of increasing concentrations of the mouse CHCR specific morpholino oligonucleotide blocked translation, with 800 mM being 100% effective. No significant reduction in protein synthesis was observed with 800 nM of the standard control oligonucleotide (Fig. 8A, compare lanes 4 and 5) . More importantly, synthesis of mouse MBNL was unaffected at all concentrations of morpholino antisense oligonucleotides examined (Fig. 8A, lanes 6 -10) . These data suggest that mCHCR-AS morpholino should serve as a selective and effective inhibitor of mCHCR protein synthesis in vivo.
FIG. 6.
Amino acid alignment of the mouse and human CHCR proteins. Sequence alignment using the Multalin and Boxshade programs illustrates the high level of similarity (88%, gray shading) and identity (81%, black shading) between the two proteins. The protein fragment used for the production of the anti-mouse CHCR antiserum is indicated by the black bar.
C2C12 cells, to be treated with morpholino antisense oligonucleotides, were seeded into six well plates in GM. The following day, the media was replaced with DM containing 0 or 10 M mCHCR-AS or a standard control morpholino oligonucleotide available from the manufacturer (GeneTool). The cells were then immediately scraped off the plates to deliver the oligonucleotides and quickly reattached to collagen-coated six-well plates in DM. After 48 h, the cells were harvested and analyzed by Western blotting. The anti-mCHCR antiserum revealed a three-to fourfold decrease in the protein levels of mCHCR in C2C12 cells treated with 10 M mCHCR-AS, but not in cells exposed to the control oligonucleotide (Figs. 8B and 8C) . Expression of the ␣-tubulin protein was unaffected by either oligonucleotide. As assessed by light microscopy, the decrease in mCHCR expression in response to treatment with the CHCR morpholino oligonucleotide did not appear to affect the morphology of C2C12 cells when compared with control oligonucleotide-treated cells. Next, we measured the differentiation potential of mCHCR-AS-and controltreated C2C12 cells by examining MyHC levels. We repeatedly observed that mCHCR-AS treatment increased the levels of MyHC in differentiating C2C12 cells approximately 2.5-fold compared with cells exposed to the control oligonucleotide (Fig. 9) . The amount of ␣-tubulin was unaffected by the antisense oligonucleotides. Our data from overexpression and antisense experiments are consistent with the hypothesis that CHCR antagonizes the process of muscle differentiation.
DISCUSSION
Using the technique of SSH, we have cloned a novel human cDNA that encodes a Cys3His zinc finger protein that we have named CHCR, for Cys3His CCG1-Required. CHCR displays significant amino acid identity to the Mbl family of proteins that are involved in muscle development. The observation that CHCR mRNA levels decrease in Reactions were subjected to SDS-PAGE, and translated proteins were detected with streptavidinconjugated horseradish peroxidase followed by chemiluminescence (Transcent Non-radioactive Translation Detection System; Promega). (B) C2C12 myoblasts were seeded into DME ϩ 10% FBS. Ten micromolar of mCHCR-AS or control (Ctrl) antisense oligonucleotide was scrape delivered, and the cells were allowed to recover overnight in GM. Media was then changed to DME containing 2% horse serum and insulin (DM) to induce cells to differentiate. After 48 h, the amount of mouse CHCR in whole cell lysates was determined by Western blotting with an anti-mouse CHCR antibody, quantitated, and normalized for ␣-tubulin levels. differentiated mouse myoblasts led us to hypothesize that CHCR is an inhibitor of the myogenic program. We have found that constitutive expression of CHCR in C2C12 mouse myoblasts inhibits the induction of the muscle specific genes, MyHC and myogenin, during muscle differentiation, while loss of CHCR function, by treatment with antisense oligonucleotides, accelerates the expression of MyHC. These two complementary findings support the hypothesis that CHCR is a negative regulator of muscle differentiation. Therefore, CHCR represents a novel member of the muscleblind family that antagonizes, instead of promotes, the process of myogenesis. These new pieces of evidence suggest that CHCR and its human Mbl homologue, EXP/MBNL, function as opposing forces, both contributing to the controlled induction of terminal muscle differentiation.
The functional importance of Mbl can be inferred from conservation of this protein throughout evolution. Sequence analysis reveals the existence of a single Mbl homologue in C. elegans and one Mbl gene in Drosophila.
Interestingly, this family expands to three members in mammals where homologues of CHCR, EXP/MBNL, and MBLL can be identified in EST and genomic databases for mouse, rat, bovine, and humans. The complexity of mammalian organisms requires a staggering number of regulatory proteins to control the vast array of signaling pathways supporting vertebrate life. The evolution of two additional Mbl proteins in vertebrates may reflect the need for regulation or modulation of Mbl function. This hypothesis is supported by the discovery that CHCR expression precedes the appearance of EXP/MBNL during muscle differentiation, providing CHCR the opportunity to negatively regulate myogenesis.
Multiple pathways that regulate the activity of myogenic regulatory factors (MRFs) and MEF-2 family members influence skeletal muscle differentiation (Perry and Rudnicki, 2000; Puri and Sartorelli, 2000) . The basic helix-loop-helix MRFs (MyoD, Myf5, myogenin, and MRF4/herculin) function in concert with the E2A and MEF-2 family of transcription factors to drive myogenic gene expression. MEF-2 family members synergize with MRFs/E2A heterodimers to activate muscle-specific gene transcription. Genetic studies in Drosophila have placed Mbl downstream of Dmef2, a MEF-2 protein, in the muscle differentiation pathway (Artero et al., 1998) . It is thus possible that, by constitutively expressing CHCR in C2C12 cells, we hindered the function of mouse MEF-2 proteins in promoting muscle differentiation.
The presence of four Cys3His motifs in CHCR also may provide some insight into its mechanism of action. Such motifs, first identified in the mRNA binding protein, tristetraprolin, have been proposed to represent unusual zinc finger domains (DuBois et al., 1990; Lim et al., 1987) . Cys3His motifs are found in a growing number of proteins present in a wide range of organisms, including trypanosomes, yeast, worms, mice, and humans. Although members of this family are involved in a variety of cellular processes, from proliferation to differentiation, many have been shown to possess RNA binding activity (Anderson et al., 1993; Bai and Tolias, 1998; Lai et al., 2000) . Tristetraprolin, the most well-characterized Cys3His containing protein, binds to the AU-rich element of the tumor necrosis factor alpha mRNA and subsequently targets the message for degradation (Carballo et al., 1998; Lai et al., 1999) . Mutagenesis of a single cysteine residue in either of two Cys3His zinc fingers completely abolishes RNA binding (Lai et al., 1999) . In Caenorhabditis elegans, the Cys3His zinc finger protein PIE-1 is a regulator of maternal and zygotic gene expression in the developing embryo (Tenenhaus et al., 2001) . Mutation of the second Cys3His zinc finger reduces PIE-1-mediated activation of protein expression from the nos-2 maternal RNA. It has been suggested that PIE-1 affects maternal RNA expression by directly binding RNA. The CHCR-related Cys3His-containing protein, EXP/MBNL, binds preferentially to the doublestranded RNA hairpins formed by CUG expansions (Miller et al., 2000; Michalowski et al., 1999; Napierala and Krzyzosiak, 1997; Tian et al., 2000) . Based on this evidence,
FIG. 9.
Treatment with mCHCR antisense oligonucleotide accelerates MyHC expression in differentiating C2C12 mouse myoblasts. (A) C2C12 myoblasts, seeded into DME ϩ 10% FBS, were treated with mCHCR-AS or control (Ctrl) antisense oligonucleotide as described in Fig. 8B and were induced to differentiate. After 48 h under differentiation conditions, cell lysates were prepared, and the levels of myosin heavy chain (MyHC) and ␣-tubulin were determined by Western blotting. The results from one representative experiment are shown (B). The relative amounts of MyHC normalized for ␣-tubulin levels from three independent experiments were determined and are shown in the graph with standard errors indicated.
CHCR may regulate muscle-specific gene expression by interacting with the transcripts of target genes. It will be of interest to examine the RNA-binding capability of CHCR both in vitro and in vivo and identify RNAs that associate with the CHCR protein.
DM1 is characterized by an expansion of CTG repeats in the 3Ј UTR of the dystrophic myotonic protein kinase (DMPK) gene (Brooks et al., 1992; Fu et al., 1992; Mahadevan et al., 1992; Meola, 2000) . Three different models have been suggested to explain how expansions in the 3Ј UTR can lead to the dominantly inherited DM1 disease. One model is that the triplet repeat expansions produce a gain-of-function RNA molecule that impairs nucleocytoplasmic mRNA export and/or sequesters nuclear factors required for proper muscle formation and maintenance (Davis et al., 1997; Mankodi et al., 2000 Mankodi et al., , 2001 Timchenko et al., 1996) . EXP/MNBL colocalizes with the CUG expansions found in mutant DMPK transcripts in DM1 cells, but not with DMPK mRNA in normal cells (Fardaei et al., 2001) . It has been proposed that the aberrant recruitment and sequestration of EXP proteins to the large CUG expansions in the DMPK transcript contributes to the DM1 phenotype. Very recently, CHCR was also found to colocalize with expanded repeat transcripts in the nuclei of DM1 cells (Fardaei et al., 2002) . These findings suggest that both CHCR and MBNL may play a role in the development of the diseased state.
We have cloned a novel cDNA that encodes a Cys3His-containing protein and provided evidence that it functions as an inhibitor of muscle differentiation. Although we have focused on CHCR's role in myogenesis, tissue expression analysis of CHCR mRNA levels in the adult mouse indicate that the message for CHCR is not restricted to the muscle lineage (R.M.S. and E.H.W., unpublished data). CHCR may thus play a general role in regulating the differentiation programs of mammalian cells.
